Six Promising Diagnostic Startups to Pitch Publicly; Winner to Receive Research Funding and Global Collaboration Opportunities.
Sharing the Latest Trends in AI-Powered Precision Diagnostics; Experts from Samsung Medical Center and Singapore National Hospital to Participate.

 

Seoul Bio Hub and Roche Diagnostics Korea continue their open innovation partnership for the third consecutive year to discover and support the growth of innovative domestic diagnostic startups.

 

Seoul Bio Hub and Roche Diagnostics Korea announced on August 21, 2026, that they will host the "2026 Seoul-Roche Diagnostics Startup Sprint Demo Day & Medical Device Innovation Technology Symposium" at the Seoul Bio Hub Global Center on September 10. This marks the third consecutive year of their open innovation partnership aimed at discovering and supporting the growth of innovative domestic diagnostic startups.

The "Seoul-Roche Diagnostics Startup Sprint Demo Day," a program launched in 2024, identifies promising startups focused on Roche Diagnostics' fields of interest and provides them with collaboration and commercialization opportunities with the global healthcare leader.

 

During the event, six shortlisted startups will participate in a public pitching session. The top-performing company will receive KRW 30 million in research funding from Seoul Bio Hub, along with a one-year residency benefit. Roche Diagnostics will offer commercialization partnership opportunities, including 1-on-1 expert mentoring, to explore global market entry potential.

The participating companies are:

• Samsun: AI-based AMH prediction and management services for female fertility.
• SynergyAI: AI solutions predicting disease risks of major blood biomarkers using daily ECG data.
• Aslon: 12-lead ECG-based AI solutions predicting coronary artery stenosis and FFR.
• Unione Pharmzen: Point-of-Care Testing (POCT) technology based on PCR amplification and molecular diagnostic materials/device platforms.
• XenoHelix: Precision diagnostic technologies for Parkinson's disease and MASLD utilizing its XENO-Q microRNA detection platform.
• ForetellMyHealth: A bio-AI company specializing in early cancer detection, ADC/immuno-oncology monitoring, and platelet-based drug discovery using platelet images and RNA.

 

The event will also feature a technology showcase and business networking. Alongside the demo day, a symposium themed "Innovation in Diagnostics: From Prediction to Decision Making" will present global bio-healthcare trends and the latest advancements in AI-based precision diagnostics.

Speakers from Roche Diagnostics, Kim & Chang, DY Prime, Samsung Medical Center Data Innovation Center, Korea Medical Institute (KMI), and the National University Hospital Research Center in Singapore will cover topics including:

• The Future of Testing & Diagnostics and Roche Diagnostics' Open Innovation
• Latest Policies and Compliance Strategies for AI-Based Diagnostic Tech
• Prerequisites for Successful Diagnostic Technologies in the Global Market
• How AI and Data Transform Hospital Decision-Making
• Domestic Screening & Diagnostic Trends and Technical Innovation Case Studies
• The Future of AI and Digital Pathology-Based Diagnostics

 

"This demo day and symposium will serve as a meaningful opportunity to understand Roche Diagnostics' open innovation direction and discover new collaboration possibilities with local innovative startups," said Hyun-woo Kim, Head of Seoul Bio Hub. "We will continuously support the selected companies by linking them with our diverse investment, commercialization, and global expansion programs."

"Through this symposium and demo day, we aim to expand our engagement with promising domestic startups and explore various collaboration opportunities centered on innovative diagnostic technologies," added Kit Tang, CEO of Roche Diagnostics Korea.

The event is open to anyone in the bio, medical device, and digital health industries, investors, and startup executives. Pre-registration is available on the official Seoul Bio Hub website.

---